Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arctic Bioscience AS ( (DE:9TD) ) has issued an update.
Arctic Bioscience announced that a clinical study published in International Ophthalmology demonstrated that daily supplementation of ROMEGA® herring roe oil significantly improved the visual field measurement Mean Deviation in patients with primary open-angle glaucoma and controlled intraocular pressure. The study involved 50 patients over three months and showed no side effects, indicating ROMEGA® may be beneficial for glaucoma patients. The company plans to conduct larger, randomized studies to further explore these promising results.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements based on unique bioactive marine raw materials. The company is working on HRO350, a new oral drug candidate for treating mild-to-moderate psoriasis, and sells dietary supplements globally under the brand ROMEGA®.
YTD Price Performance: 79.88%
Average Trading Volume: 29,287
Current Market Cap: NOK88.37M
Learn more about 9TD stock on TipRanks’ Stock Analysis page.